Literature DB >> 22940407

Targeting gut flora to prevent progression of hepatocellular carcinoma.

Marion Darnaud1, Jamila Faivre, Nicolas Moniaux.   

Abstract

Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma(HCC), a long-term consequence of chronic liver injury, inflammation,and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in nonbone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.

Entities:  

Year:  2012        PMID: 22940407     DOI: 10.1016/j.jhep.2012.08.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  29 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

Review 3.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

Review 4.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 5.  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Authors:  Abigale Lade; Luke A Noon; Scott L Friedman
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

6.  Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment.

Authors:  Wen-Ting Liu; Ying-Ying Jing; Lu Gao; Rong Li; Xue Yang; Xiao-Rong Pan; Yang Yang; Yan Meng; Xiao-Juan Hou; Qiu-Dong Zhao; Zhi-Peng Han; Li-Xin Wei
Journal:  Cell Death Differ       Date:  2019-05-07       Impact factor: 15.828

Review 7.  Hepatic stellate cells: central modulators of hepatic carcinogenesis.

Authors:  Alexandra I Thompson; Kylie P Conroy; Neil C Henderson
Journal:  BMC Gastroenterol       Date:  2015-05-27       Impact factor: 3.067

Review 8.  Role of toll-like receptors in immune activation and tolerance in the liver.

Authors:  Nobuhiro Nakamoto; Takanori Kanai
Journal:  Front Immunol       Date:  2014-05-16       Impact factor: 7.561

9.  Intestinal microbial variation may predict early acute rejection after liver transplantation in rats.

Authors:  Zhigang Ren; Jianwen Jiang; Haifeng Lu; Xinhua Chen; Yong He; Hua Zhang; Haiyang Xie; Weilin Wang; Shusen Zheng; Lin Zhou
Journal:  Transplantation       Date:  2014-10-27       Impact factor: 4.939

Review 10.  The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease.

Authors:  María Teresa Arias-Loste; Emilio Fábrega; Marcos López-Hoyos; Javier Crespo
Journal:  Biomed Res Int       Date:  2015-09-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.